Abstract
Invasive pneumococcal disease (IPD) causes significant morbidity in Canada, yet even with routine surveillance, it is difficult to interpret current IPD trends in serotype distribution and antimicrobial resistance. The enhanced Invasive Pneumococcal Disease Surveillance System (eIPDSS) pilot project was designed to facilitate a better understanding of IPD trends at the national level by linking epidemiologic and laboratory (epi-lab) data. To evaluate the eIPDSS by assessing five attributes (usefulness, data quality, simplicity, acceptability and timeliness) and to develop recommendations for future national IPD surveillance. An evaluation was developed that assessed the five key attributes through a qualitative survey sent to eight eIPDSS users as well as a quantitative analysis of the eIPDSS database. Recommendations were based on the results of both the survey and the analysis. The response rate to the survey was 100%. The majority of the survey respondents found the eIPDSS to be useful (75%), simple (100%) and acceptable (86%). Analysis of the eIPDSS database revealed that the majority of IPD cases (61%) were assessed as timely. Data quality and data management mechanisms were identified as issues by both survey respondents and the analysis of the database. Consultation with public health, regular audits and upgrades to the platform are recommended to address data quality and management issues. The epi-lab linked data of the eIPDSS enables the detection and analysis of IPD serotype distribution and antimicrobial resistance trends. This web-based system facilitates data collection and is simple, acceptable and timely. With improvements that address data quality and management issues, it is feasible to develop a national surveillance system that links epi-lab data.
Highlights
Invasive pneumococcal disease (IPD) is an infectious disease caused by Streptococcus pneumoniae, which can cause severe morbidity and mortality, especially among young children and the elderly
While Canada is experiencing a decrease in incidence of IPD that is reflective of an effective immunization program (5), the rising incidence of non-vaccine serotypes and antimicrobial resistan (AMR) serotypes are of particular concern
This framework was designed to assess five important attributes -- usefulness and data quality were selected to assess whether the enhanced Invasive Pneumococcal Disease Surveillance System (eIPDSS) is effective in collecting epi-lab linked data; simplicity, acceptability and timeliness were selected to assess the feasibility of developing a national IPD surveillance system that links epidemiologic and laboratory data
Summary
Invasive pneumococcal disease (IPD) is an infectious disease caused by Streptococcus pneumoniae, which can cause severe morbidity and mortality, especially among young children and the elderly. An estimated 1.6 million people, including one million children less than five years of age, die of IPD annually (1). IPD has been nationally notifiable in Canada since 2000 (2) and is vaccine-preventable. There are currently 92 serotypes of S. pneumoniae recognized worldwide, 15 of which cause the majority of disease in Canada. Invasive pneumococcal disease (IPD) causes significant morbidity in Canada, yet with routine surveillance, it is difficult to interpret current IPD trends in serotype distribution and antimicrobial resistance. The enhanced Invasive Pneumococcal Disease Surveillance System (eIPDSS) pilot project was designed to facilitate a better understanding of IPD trends at the national level by linking epidemiologic and laboratory (epi-lab) data
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Canada communicable disease report = Releve des maladies transmissibles au Canada
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
